New data on the link between COVID-19 vaccines and myopericarditis – Cardiovascular Business

Overall, the group identified 12 cases of myopericarditis in vaccinated study participants. Three of those cases came after the first dose of a COVID-19 vaccine, seven cases came after the second dose and the other two cases came after a single-dose vaccine. Meanwhile, there were five cases of myopericarditis reported in the control group.

The age-adjusted incidence rate of myopericarditis among men was higher in the vaccinated group than in the studys control group. This was not, however, the case among women.

Previous research has demonstrated that there are slightly higher rates of myopericarditis of any cause in men than in women, the authors wrote. One proposed potential mechanism for this difference in incidence is that the higher levels of estradiol in women may confer a cardioprotective effect. If COVID-19 vaccination is a causative factor in the development of myopericarditis in some people, the same mechanisms may be making men more susceptible than women after COVID-19 vaccination.

The team did note that this was not a randomized controlled trial. Also, using study subjects as their own controls likely kept selection bias to a minimum, but it does mean that all patients were two years old after they had been vaccinated.

Even with these limitations in mind, the authors said their work reaffirms the apparent increase in the diagnosis of myopericarditis in men (particularly aged 25 to 44 years) after COVID-19 vaccination.

They concluded, however, by highlighting the continued importance of these vaccines.

The benefits of COVID-19 vaccination to individual and public health outweigh the very small risks of myopericarditis diagnosed after vaccination, they concluded.

Read the full analysis here.

Read the original post:

New data on the link between COVID-19 vaccines and myopericarditis - Cardiovascular Business